Therapy influences goal attainment following botulinum neurotoxin injection for focal spasticity in adults with neurological conditions

Brain Inj. 2018;32(7):948-956. doi: 10.1080/02699052.2018.1469044. Epub 2018 May 2.

Abstract

Objective: To determine whether therapy influenced goal attainment following botulinum toxin (BoNT-A) injection for focal spasticity in adults with neurological conditions.

Methods: A prospective observational cohort study conducted in a large metropolitan spasticity clinic on adults with focal spasticity of any origin. Participants were provided with a therapy programme, designed to maximise therapeutic outcome. The primary outcome measure was Goal Attainment Scaling. To measure adherence, participants completed a therapy-recording tool each day. Goal attainment, and the rate of adherence to the therapy programme, was evaluated after 10 weeks.

Results: Active indications for BoNT-A treatment made up the majority of the goals (80.30%). Goals were achieved in 43/76 cases (56.60%; 95% CI = 42.40 to 69.80%). Therapy adherence was associated with significantly greater goal attainment (OR = 1.02, p = 0.03, 95% CI = 1.00 to 1.04). Greater adherence to therapy increased the odds of goal achievement for active indications but not for passive indications, suggesting a possible statistical interaction between the indication for injection and adherence to therapy (p < 0.01).

Conclusion: Therapy adherence was associated with greater goal attainment. Active indications for BoNT-A were more reliant on adherence to prescribed therapy programmes than passive indications, although further investigation is required.

Keywords: Spasticity; botulinum toxin; goal attainment; rehabilitation; therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Botulinum Toxins, Type A / therapeutic use*
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Goals*
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology*
  • Nervous System Diseases / complications*
  • Nervous System Diseases / rehabilitation
  • Neuromuscular Agents / therapeutic use*
  • Outcome Assessment, Health Care
  • Patient Compliance
  • Severity of Illness Index
  • Treatment Outcome*
  • Young Adult

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A